Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

04.04.18	Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes (PR Newswire)
04.04.18	Eli Lilly: CYRAMZA Phase 3 REACH-2 Study Meets Primary Endpoint - Quick Facts (RTTNews)
04.04.18	Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint (PR Newswire)
03.04.18	Improving Cardiology Care: BIOTRONIK US to Distribute Aziyo ECM Envelopes (PR Newswire)
03.04.18	Will These Drugs Reach Blockbuster Status? (RTTNews)
28.03.18	Biotech Stocks Facing FDA Decision In April (RTTNews)
23.03.18	Un plan audacieux pour le Québec! - Plan d'action gouvernemental en entrepreneuriat (PR Newswire)
09.03.18	Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology (PR Newswire)
08.03.18	EFSD, JDRF, Lilly Extend Collaboration Supporting Type 1 Diabetes Research (RTTNews)
08.03.18	EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research (PR Newswire)
06.03.18	Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials (PR Newswire)
26.02.18	Eli Lilly Announces Additional FDA Approval For Verzenio - Quick Facts (RTTNews)
26.02.18	Lilly Receives Additional FDA Approval for VerzenioTM (abemaciclib), as Initial Treatment for Advanced Breast Cancer (PR Newswire)
26.02.18	Eli Lilly Reports New Data From Trulicity Phase 3b Study - Quick Facts (RTTNews)
26.02.18	New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes (PR Newswire)
21.02.18	Lilly to Participate in Barclays Global Healthcare Conference (PR Newswire)
20.02.18	Lilly to Participate in Cowen Health Care Conference (PR Newswire)
20.02.18	Survey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month (PR Newswire)
19.02.18	Eli Lilly: Taltz Improves Sexual Health Of Genital Psoriasis Patients (RTTNews)
19.02.18	AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity (PR Newswire)
14.02.18	Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting (PR Newswire)
13.02.18	Eli Lilly: Taltz Phase 3 Study Meets Endpoints To Treat Ankylosing Spondylitis (RTTNews)
13.02.18	Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) (PR Newswire)
31.01.18	Lilly Lifts 2018 Profit View; Backs Revenue Outlook (RTTNews)
31.01.18	Eli Lilly And Co. Profit Rises In Q4 (RTTNews)
31.01.18	Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance (PR Newswire)
26.01.18	Lilly To Present At Leerink Partners Global Healthcare Conference (PR Newswire)
26.01.18	Elanco Announces Global Agreement with Ab E Discovery for New Technology (PR Newswire)
22.01.18	Eli Lilly Animal Health Unit Announces FDA Approval Of Credelio - Quick Facts (RTTNews)
22.01.18	Elanco Animal Health Announces U.S. Food and Drug Administration (FDA) Approval of Credelio® (lotilaner) to Treat and Protect Against Ticks and Fleas (PR Newswire)
22.01.18	Some Branded Drugs Going Generic In 2018 (RTTNews)
18.01.18	Elanco Innovations Named Best Products for 2017 (PR Newswire)
18.01.18	GALLIPRANT® (grapiprant tablets) Named Best Companion Animal Product for 2017 (PR Newswire)
15.01.18	Federal-Mogul Motorparts' Abex® Brand Introduces New Brake Rotors for Commercial Vehicle Market (PR Newswire)
11.01.18	Elanco Announces Addition of New North America and Global Strategy Senior Executive (PR Newswire)
11.01.18	Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe (PR Newswire)
08.01.18	Livongo and Lilly Collaborate on Real-World Diabetes Research (PR Newswire)
05.01.18	Lilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results Announcement (PR Newswire)
02.01.18	Vancouver Island 2018 Property Assessment Notices in the Mail (PR Newswire)
18.12.17	Lilly to Participate in Goldman Sachs Healthcare CEOs Unscripted Conference (PR Newswire)
14.12.17	Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin (PR Newswire)
13.12.17	Lilly Cuts 2017 EPS View; Announces Outlook Through 2020 (RTTNews)
13.12.17	Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020 (PR Newswire)
11.12.17	Lilly Announces 8 Percent Dividend Increase (PR Newswire)
11.12.17	Eli Lily: FDA Accepts BLA To Review Galcanezumab For Prevention Of Migraine (RTTNews)
11.12.17	FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults (PR Newswire)
11.12.17	Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology (PR Newswire)
08.12.17	Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer (PR Newswire)
05.12.17	Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System (PR Newswire)
01.12.17	Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		SIX-Handel: SLI zeigt sich zum Ende des Freitagshandels fester
22.11.24		Pluszeichen in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen
22.11.24		Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen
22.11.24		Deutsche Bank AG: Novartis-Aktie erhält Hold
22.11.24		Freitagshandel in New York: Dow Jones zum Start des Freitagshandels fester
22.11.24		Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag
22.11.24		Pluszeichen in Europa: STOXX 50 notiert im Plus

22.11.24

Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone

22.11.24

SIX-Handel: SLI zeigt sich zum Ende des Freitagshandels fester

22.11.24

Pluszeichen in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen

22.11.24

Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen

22.11.24

Deutsche Bank AG: Novartis-Aktie erhält Hold

22.11.24

Freitagshandel in New York: Dow Jones zum Start des Freitagshandels fester